Expanded informed consent for medications

Summary#

The Written Informed Consent Act is a bill that would direct the Secretary of Veterans Affairs to update an existing Veterans Health Administration (VHA) directive, not create a new agency or program. The bill’s stated goal is to expand the directive on informed consent for long-term opioid therapy to cover five additional medication categories. It has not become law, and passage is uncertain.

  • The Secretary must update VHA Directive 1005, dated May 13, 2020, to apply to antipsychotics, stimulants, antidepressants, anxiolytics, and narcotics.
  • The bill does not itself spell out what information patients must receive, how consent must be given, or when the directive applies to each medication.
  • It does not directly change veterans’ eligibility for medication, prescribing rules, or access to treatment.

What it means for you#

  • Veterans receiving the named medications: If enacted, the updated directive would apply to these medication categories. The bill does not say exactly what steps a veteran or clinician would have to take.
  • VA and VHA: The VA Secretary would have to update the directive. The bill gives no deadline.
  • Other patients and health providers: The bill addresses a VHA directive. It does not directly change rules for non-VA providers.

Money#

No cost information is in the available material.

  • The bill would require the VA Secretary to update the directive, but it gives no estimate for staff time or other costs.
  • It does not specify new funding, fees, fines, or savings.

What is unclear#

  • The text of VHA Directive 1005 was not provided, so its current requirements—and which parts the bill would extend—could not be verified.
  • The bill does not define “narcotics” or the other medication categories.
  • It does not set a deadline or explain what the directive must require for informed consent, including whether consent must be written.
  • It does not explain how the update would apply when a patient takes more than one listed medication or when medication use is short-term.
  • The bill does not describe oversight, reporting, or how veterans could raise concerns about the updated directive.

Case for#

  • The bill appears intended to extend an existing VHA informed-consent directive beyond long-term opioid therapy to five other medication categories.
  • A possible argument for the bill is that applying the directive to more medication categories could give patients and clinicians a consistent process for informed consent.
  • The bill assigns the update to the VA Secretary, who is responsible for the directive.

Case against#

  • The bill does not say what the expanded informed-consent process must include, so its practical effect depends on the later update.
  • The medication categories are not defined, and “narcotics” may overlap with the opioid therapy already covered by the directive.
  • The bill gives no deadline, cost estimate, or details about how the change would fit with existing VA practices.